Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALZN NASDAQ:ENSC NASDAQ:EVFM NASDAQ:GOVX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALZNAlzamend Neuro$1.16$1.15$0.84▼$3.60$4.41M0.14322,361 shs371,030 shsENSCEnsysce Biosciences$0.28$0.31$0.23▼$2.75$4.36M0.781.02 million shs314,348 shsEVFMEvofem Biosciences$0.01$0.01$0.00▼$0.02$1.06M-1.33222,576 shs614,709 shsGOVXGeoVax Labs$1.19$1.64$0.96▼$23.10$4.13M3.68632,131 shs301,596 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALZNAlzamend Neuro0.00%-3.33%+1.75%+16.01%-61.33%ENSCEnsysce Biosciences0.00%-5.62%-4.76%-53.41%-87.49%EVFMEvofem Biosciences0.00%-2.44%-5.88%-3.61%-20.00%GOVXGeoVax Labs0.00%-10.05%-33.52%-10.53%-90.02%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALZNAlzamend Neuro$1.16$1.15$0.84▼$3.60$4.41M0.14322,361 shs371,030 shsENSCEnsysce Biosciences$0.28$0.31$0.23▼$2.75$4.36M0.781.02 million shs314,348 shsEVFMEvofem Biosciences$0.01$0.01$0.00▼$0.02$1.06M-1.33222,576 shs614,709 shsGOVXGeoVax Labs$1.19$1.64$0.96▼$23.10$4.13M3.68632,131 shs301,596 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALZNAlzamend Neuro0.00%-3.33%+1.75%+16.01%-61.33%ENSCEnsysce Biosciences0.00%-5.62%-4.76%-53.41%-87.49%EVFMEvofem Biosciences0.00%-2.44%-5.88%-3.61%-20.00%GOVXGeoVax Labs0.00%-10.05%-33.52%-10.53%-90.02%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALZNAlzamend Neuro 2.00Hold$28.002,313.79% UpsideENSCEnsysce Biosciences 1.00SellN/AN/AEVFMEvofem Biosciences 0.00N/AN/AN/AGOVXGeoVax Labs 1.50Reduce$150.0012,505.04% UpsideCurrent Analyst Ratings BreakdownLatest EVFM, ALZN, ENSC, and GOVX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/29/2026ALZNAlzamend Neuro Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)6/11/2026ALZNAlzamend Neuro Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)5/21/2026ALZNAlzamend Neuro Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)5/6/2026ALZNAlzamend Neuro Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)4/21/2026ENSCEnsysce Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026GOVXGeoVax Labs Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/16/2026GOVXGeoVax Labs D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold(Data available from 7/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALZNAlzamend NeuroN/AN/AN/AN/A$4.95 per shareN/AENSCEnsysce Biosciences$5.07M0.86N/AN/A$0.63 per share0.45EVFMEvofem Biosciences$11.39M0.09N/AN/A($2.64) per share0.00GOVXGeoVax Labs$2.49M1.66N/AN/A$2.21 per share0.54Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALZNAlzamend Neuro-$4.51M-$2.16N/AN/AN/AN/A-177.52%-140.41%7/28/2026 (Estimated)ENSCEnsysce Biosciences-$10.18M-$3.35N/AN/AN/A-250.39%-766.45%-256.59%8/12/2026 (Estimated)EVFMEvofem Biosciences$52.98M-$0.07N/AN/AN/A-46.42%-91.97%-61.93%N/AGOVXGeoVax Labs-$21.47M-$19.12N/AN/AN/AN/A-709.52%-399.33%7/27/2026 (Estimated)Latest EVFM, ALZN, ENSC, and GOVX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/28/2026Q4 2026ALZNAlzamend Neuro-$0.67N/AN/AN/AN/AN/A7/27/2026Q2 2026GOVXGeoVax Labs-$2.16N/AN/AN/AN/AN/A5/15/2026Q1 2026ENSCEnsysce Biosciences-$0.73-$0.52+$0.21-$0.52$1.00 million$0.96 million5/14/2026Q4 2025GOVXGeoVax Labs-$3.8421-$2.62+$1.2221-$2.62N/AN/A4/15/2026Q4 2025GOVXGeoVax LabsN/A$1.85N/A$1.85N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALZNAlzamend NeuroN/AN/AN/AN/AN/AENSCEnsysce BiosciencesN/AN/AN/AN/AN/AEVFMEvofem BiosciencesN/AN/AN/AN/AN/AGOVXGeoVax LabsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALZNAlzamend NeuroN/A1.991.99ENSCEnsysce BiosciencesN/A0.710.71EVFMEvofem BiosciencesN/A0.110.09GOVXGeoVax LabsN/A1.061.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALZNAlzamend Neuro49.61%ENSCEnsysce Biosciences5.63%EVFMEvofem Biosciences0.22%GOVXGeoVax Labs6.09%Insider OwnershipCompanyInsider OwnershipALZNAlzamend Neuro1.39%ENSCEnsysce Biosciences2.80%EVFMEvofem Biosciences0.01%GOVXGeoVax Labs0.69%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALZNAlzamend Neuro43.80 million3.75 millionNo DataENSCEnsysce Biosciences1015.37 million14.94 millionNot OptionableEVFMEvofem Biosciences120132.53 million113.12 millionNot OptionableGOVXGeoVax Labs103.47 million3.45 millionNot OptionableEVFM, ALZN, ENSC, and GOVX HeadlinesRecent News About These CompaniesGeoVax Highlights Continued U.S. Government Investment in Orthopox Preparedness as Strategic Validation of Long-Term Vaccine ReadinessJuly 1, 2026 | finance.yahoo.comGeoVax Labs Inc. (NASDAQ:GOVX) Short Interest UpdateJune 29, 2026 | americanbankingnews.comGeoVax Labs (GOVX) Stock Fair Value Moves Lower After Pipeline ShiftJune 27, 2026 | uk.finance.yahoo.comGeoVax Highlights Strategic Implications of Recent Gedeptin(R) Findings for Checkpoint-Resistant CancersJune 17, 2026 | finance.yahoo.comGeoVax Labs (GOVX) Could Find a Support Soon, Here's Why You Should Buy the Stock NowJune 12, 2026 | zacks.comGeoVax Highlights Peer-Reviewed Research Supporting Gedeptin(R) Potential to Enhance Cancer Immunotherapy ResponsesJune 8, 2026 | finance.yahoo.comGeoVax CEO Welcomes FIFA World Cup 2026 While Addressing Biothreat ReadinessJune 1, 2026 | finance.yahoo.comRegistration Now Open for Tribe Public CEO Presentation and Q&A Webinar EventMay 28, 2026 | finance.yahoo.comGeoVax Labs, Inc. (GOVX) Discusses Building a Resilient Infectious Disease Preparedness Strategy Focused on Ebola, Marburg, Hantavirus, and Mpox TranscriptMay 28, 2026 | seekingalpha.comGeoVax Accelerates Focus on GEO-MVA Commercialization and Advancement of Oncology Program Gedeptin(R)May 26, 2026 | finance.yahoo.comWhy is GOVX stock falling today?May 26, 2026 | msn.comHow The GeoVax Labs (GOVX) Story Is Shifting With Vaccine Progress And Funding RisksMay 26, 2026 | finance.yahoo.comGeoVax Comments on Escalating Bundibugyo Ebola Outbreak and Growing Need for Flexible Biodefense Vaccine PlatformsMay 21, 2026 | theglobeandmail.comGeoVax Stock Higher As Company Highlights MVA Platform For Ebola ThreatsMay 20, 2026 | benzinga.comGOVX stock soars 80%: Retail traders are piling in as Ebola, hantavirus risks resurfaceMay 19, 2026 | msn.comGeoVax Announces $3 Million Private Placement Financing Priced At-the-Market Under Nasdaq RulesMay 18, 2026 | finance.yahoo.comGeoVax Highlights Strategic Importance of Domestic MVA-Based Preparedness Infrastructure Amid Escalating Global Infectious Disease ThreatsMay 18, 2026 | finance.yahoo.comGeoVax Reports First Quarter 2026 Financial Results and Highlights GEO-MVA Phase 3 Trial Implementation PlansMay 15, 2026 | finance.yahoo.comAll You Need to Know About GeoVax Labs (GOVX) Rating Upgrade to BuyMay 15, 2026 | zacks.comGeoVax Highlights Emerging Role of Gedeptin(R) in Combination Immunotherapy Strategies Targeting Immunologically Cold TumorsMay 14, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEVFM, ALZN, ENSC, and GOVX Company DescriptionsAlzamend Neuro NASDAQ:ALZN$1.16 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$1.13 -0.03 (-2.67%) As of 07/2/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.Ensysce Biosciences NASDAQ:ENSC$0.28 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$0.29 +0.01 (+1.76%) As of 07/2/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.Evofem Biosciences NASDAQ:EVFM$0.0080 0.00 (0.00%) As of 07/2/2026 03:13 PM EasternEvofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.GeoVax Labs NASDAQ:GOVX$1.19 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$1.22 +0.03 (+2.10%) As of 07/2/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/29 - 07/03 Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst This Under-the-Radar Industrial Is Quietly Powering AI SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential Why the Comcast Spin-Off Won't Fix What's Actually Broken Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
